Switching to anastrozole after tamoxifen improves survival in postmenopausal women with breast cancer

被引：5
|
作者：
Boccardo, F. [1 ,2 ]
机构：
[1] Univ Genoa, Dept Oncol Biol & Genet, I-16132 Genoa, Italy
[2] Natl Inst Canc Res, Acad Unit Med Oncol, Genoa, Italy
来源：
NATURE CLINICAL PRACTICE ONCOLOGY | 2008年 / 5卷 / 02期
关键词：
D O I：
10.1038/ncponc1015
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：76 / 77
页数：2
相关论文
共 50 条
  • [21] Randomised study of anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women
    Vergote, I
    Bonneterre, J
    Thürlimann, B
    Robertson, J
    Krzakowski, M
    Mauriac, L
    Koralewski, L
    Webster, A
    Steinberg, M
    von Euler, M
    EUROPEAN JOURNAL OF CANCER, 2000, 36 : S84 - S85
  • [22] Comparison of adverse effects on lipid metabolism of Anastrozole with Tamoxifen in adjuvant setting for postmenopausal women with early breast cancer
    不详
    EJC SUPPLEMENTS, 2006, 4 (02): : 94 - 94
  • [23] Meta-analysis of trials comparing anastrozole and tamoxifen for adjuvant treatment of postmenopausal women with early breast cancer
    Adnan Aydiner
    Faruk Tas
    Trials, 9
  • [24] Meta-analysis of trials comparing anastrozole and tamoxifen for adjuvant treatment of postmenopausal women with early breast cancer
    Aydiner, Adnan
    Tas, Faruk
    TRIALS, 2008, 9 (1)
  • [25] Anastrozole is superior to tamoxifen in the treatment of postmenopausal women with early breast cancer - first results of the ATAC ('Arimidex', Tamoxifen, alone or in combination) trial
    Sainsbury, R
    INTERNATIONAL JOURNAL OF CANCER, 2002, : 137 - 137
  • [26] Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: Long term results of the Italian Tamoxifen Anastrozole trial
    Boccardo, F.
    Guglielmini, P.
    Bordonaro, R.
    Fini, A.
    Massidda, B.
    Porpiglia, M.
    Roagna, R.
    Serra, P.
    Orzalesi, L.
    Ucci, G.
    Rubagotti, A.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 (07) : 1546 - 1554
  • [27] Switching to exemestane after 2-3 years of adjuvant tamoxifen prolongs disease-free survival, but not overall survival, in postmenopausal women surviving primary breast cancer, compared with continuous tamoxifen
    Davies, C
    CANCER TREATMENT REVIEWS, 2004, 30 (06) : 583 - 588
  • [28] Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial
    Jakesz, R
    Jonat, W
    Gnant, M
    Mittlboeck, M
    Greil, R
    Tausch, C
    Hilfrich, J
    Kwasny, W
    Menzel, C
    Samonigg, H
    Seifert, M
    Gademann, G
    Kaufmann, M
    LANCET, 2005, 366 (9484): : 455 - 462
  • [29] Anastrozole versus tamoxifen as first-line therapy for postmenopausal advanced breast cancer
    Bergmann, L
    STRAHLENTHERAPIE UND ONKOLOGIE, 2001, 177 (05) : 273 - 274
  • [30] Sex hormones in postmenopausal women with breast cancer on tamoxifen
    KostoglouAthanassiou, I
    Ntalles, K
    Gogas, J
    Markopoulos, C
    AlevizouTerzaki, V
    Athanassiou, P
    Georgiou, E
    Proukakis, C
    HORMONE RESEARCH, 1997, 47 (03) : 116 - 120
12345